54
Participants
Start Date
April 30, 2015
Primary Completion Date
July 31, 2018
Study Completion Date
July 31, 2018
0.5mg intravitreal ranibizumab
Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
ZhongShan Ophthalmic Center, Sun Yat-sen University, Guangzhou
Zhongshan Ophthalmic Center, Sun Yat-sen University
OTHER